Aura Biosciences

First pharmacological treatment for ocular melanoma

Aura is developing a first-in-class treatment for ocular melanoma and other ocular cancers based on a photo-activatable dye conjugated to HPV-derived nanoparticles that target tumour cells in the eye.

Aura’s lead product will enter clinical testing in early 2017. It is potentially the first alternative to the current treatment options of either radiotherapy or enucleation.

CEO  Elisabet de los Pinos

Advent Contact  Raj Parekh

Advent invested in the Series B in 2015.
Publicly Listed
7 December 2023 in Aura Biosciences, Press Release, Private Companies

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial

Press Release.   Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal…
Read More
6 November 2023 in Aura Biosciences, Press Release, Private Companies

Aura Biosciences Receives FDA Agreement for CoMpass Phase 3 Clinical Trial

Press Release.   Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma November 6, 2023…
Read More
29 March 2023 in Aura Biosciences, Press Release, Private Companies, Publicly Listed

Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013

Press Release.   ZKN-013 in development for treatment of recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB) Additional IND filing for ZKN-013 for treatment of familial adenomatous polyposis…
Read More
16 February 2023 in Aura Biosciences, Press Release, Private Companies, Publicly Listed

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

Press Release.   Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal…
Read More